Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas
V. W. Rebecca, M. Xiao, A. Kossenkov, T. Godok, G. S. Brown, D. Fingerman, G. M. Alicea, M. Wei, H. Ji, J. Bravo, Y. Chen, M. E. Fane, J. Villanueva, K. L. Nathanson, Q. Liu, , M. Herlyn
The paper identifies dasatinib as effective in restoring BRAFi/MEKi antitumor efficacy in 70% of resistant PDX models by targeting proteins involved in therapy escape.
bioRxiv · Jan 20, 2023 · PreprintCancer Biology